Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $62.54 | $18.43 | 239.32% | 260.58x | 18.87x | 19.11x | 51.22x | 1.23x | $41.15M | 0.75% | $108.58M | 1.23 | $5.52B | 103.05 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $303.64 | $94.98 | 219.70% | 69.64x | 41.17x | 9.41x | 37.70x | 1.43x | $641.34M | 1.59% | $1.08B | 8.09 | $41.80B | 45.21 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $6.15 | $2.85 | 116.01% | 87.86x | 51.46x | 3.33x | 81.60x | 0.84x | $47.52M | 4.54% | $13.01M | 0.08 | $1.21B | 22.62 | ||
| CORT | CORCEPT THERAPEUTICS INC | $74.89 | $19.00 | 294.22% | 162.80x | 143.03x | 10.17x | 12.60x | 1.53x | $119.79M | 1.53% | $637.99M | 6.11 | $7.94B | -1,156.49 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $49.23 | $17.46 | 181.93% | 50.23x | 38.56x | 5.00x | 6.25x | 1.36x | $164.23M | 4.36% | $605.69M | 7.92 | $3.61B | 32.35 | ||
| KRYS | KRYSTAL BIOTECH INC | $307.79 | $96.44 | 219.17% | 39.71x | 38.07x | 21.60x | 7.11x | 1.89x | $237.38M | 2.63% | $1.28B | 43.59 | $8.58B | 40.11 | ||
| ADMA | ADMA BIOLOGICS INC | $7.98 | $10.57 | -24.51% | 11.57x | 8.04x | 3.69x | 4.74x | 0.39x | $107.90M | 5.73% | $390.33M | 1.65 | $1.91B | 8.62 | ||
| HALO | HALOZYME THERAPEUTICS INC | $71.60 | $71.09 | 0.72% | 24.19x | 8.64x | 5.61x | 38.67x | 0.44x | $667.65M | 7.89% | $219.64M | 1.86 | $10.33B | 16.55 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $56.47 | $41.16 | 37.18% | 40.34x | 14.21x | 3.35x | 1.76x | 0.57x | $767.06M | 7.06% | $6.21B | 32.27 | $9.27B | 19.22 | ||
| RPRX | ROYALTY PHARMA PLC | $55.02 | $40.21 | 36.84% | 28.81x | 10.32x | 9.85x | 3.19x | 0.62x | $2.34B | 9.74% | $9.94B | 22.75 | $40.05B | 34.43 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $11.17 | $16.39 | -31.86% | 5.45x | 23.77x | 5.33x | 3.21x | 0.69x | $56.42M | 8.65% | $205.80M | 3.52 | $565.87M | 3.91 | ||
| VCEL | VERICEL CORP | $35.69 | $9.21 | 287.49% | 83.00x | 74.03x | 6.20x | 5.12x | 1.75x | $47.49M | 2.62% | $356.23M | 7.02 | $1.81B | 44.73 | ||
| OMER | OMEROS CORP | $10.25 | $15.65 | -34.51% | 7.88x | -26.92x | 74.28x | -11.71x | 0.40x | -$94.78M | -12.86% | -$63.33M | -0.88 | $1.05B | 11.62 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $235.91 | $96.47 | 144.55% | 29.86x | 26.18x | 17.09x | 4.74x | 1.47x | $122.22M | 2.61% | $997.32M | 50.16 | $5.06B | 22.46 | ||
| ASND | ASCENDIS PHARMA A | $218.84 | $84.45 | 159.12% | 23.19x | 17.62x | 13.34x | 23.68x | 2.16x | $52.94M | 0.39% | $574.09M | 9.24 | $13.97B | 149.84 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $240.06 | $49.14 | 388.49% | 510.77x | 9.30x | 3.35x | 3.32x | 1.74x | $1.30B | 8.73% | $4.53B | 73.22 | $18.62B | 27.58 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.98 | $5.78 | -48.46% | 11.04x | 4.36x | 2.79x | 3.26x | 0.23x | $7.24M | 4.23% | $52.93M | 0.92 | $118.89M | 7.67 | ||
| TECH | BIO-TECHNE CORP | $53.18 | $15.51 | 242.84% | 74.90x | 27.05x | 6.87x | 3.99x | 1.53x | $269.60M | 3.24% | $2.09B | 13.34 | $8.41B | 32.84 | ||
| TGTX | TG THERAPEUTICS INC | $40.56 | $18.77 | 116.07% | 12.60x | 27.02x | 8.36x | 10.65x | 8.24x | -$14.19M | -0.24% | $583.13M | 4.04 | $6.52B | 43.45 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $32.96 | $36.15 | -8.82% | 13.03x | 8.98x | 2.12x | 2.10x | 0.49x | $341.79M | 17.93% | $910.35M | 15.75 | $1.48B | 6.24 | ||
| UTHR | UNITED THERAPEUTICS CORP | $547.69 | $249.36 | 119.64% | 18.71x | 18.84x | 7.52x | 3.94x | 1.98x | $1.02B | 4.27% | $5.90B | 135.66 | $21.97B | 12.82 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $441.74 | $171.11 | 158.16% | 25.97x | 22.58x | 9.19x | 5.79x | 1.85x | $3.71B | 3.31% | $19.36B | 76.20 | $108.61B | 20.14 | ||
| EXEL | EXELIXIS INC | $52.49 | $31.09 | 68.81% | 16.82x | 15.93x | 5.71x | 6.82x | 1.22x | $917.69M | 6.77% | $1.94B | 7.49 | $13.14B | 12.44 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.50 | $2.48 | 41.16% | 14.58x | 14.79x | 2.14x | 3.39x | 0.98x | $4.11M | 1.46% | $82.33M | 1.03 | $214.78M | 10.11 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.29 | $15.02 | 108.33% | 17.29x | 16.27x | 6.41x | 3.78x | 1.96x | $208.13M | 5.44% | $1.01B | 8.28 | $3.08B | 9.18 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.01 | $1.76 | 14.49% | 10.58x | 9.25x | 2.10x | 2.41x | 0.91x | $13.00M | 8.11% | $67.23M | 0.84 | $128.72M | 5.77 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $628.73 | $446.47 | 40.82% | 14.77x | 13.30x | 4.38x | 2.10x | 0.97x | $4.11B | 6.29% | $31.42B | 302.15 | $65.66B | 11.43 | ||
| VCYT | VERACYTE INC | $49.94 | $12.44 | 301.49% | 44.99x | 44.38x | 7.33x | 2.96x | 2.59x | $155.34M | 3.91% | $1.34B | 16.90 | $3.76B | 32.68 | ||
| INCY | INCYTE CORP | $101.24 | $66.68 | 51.83% | 13.89x | 12.85x | 3.76x | 3.60x | 1.23x | $1.45B | 7.19% | $5.62B | 28.21 | $16.80B | 8.98 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $16.66 | $4.64 | 259.22% | 27.77x | 4.78x | 0.80x | 1.17x | 3.89x | $109.24M | 6.24% | $1.51B | 14.34 | $2.33B | 28.18 | ||
| MDXG | MIMEDX GROUP INC | $3.78 | $1.57 | 140.12% | 18.00x | -52.94x | 1.44x | 2.32x | 2.79x | $69.36M | 12.35% | $242.94M | 1.64 | $420.84M | 7.73 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.